×

Sign In

Search
Home

Abbvie to record $3.5 billion charge related to schizophrenia drug

By Thomson Reuters Jan 10, 2025 | 7:44 AM

(Reuters) – Abbvie said on Friday it will record a charge of about $3.5 billion related to its experimental schizophrenia drug, emraclidine, which recently failed in two mid-stage studies.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Shreya Biswas)

Delta resumes flights at Atlanta hub, cancels 700 flights

FTC weighs in on Musk's lawsuit against OpenAI

US Supreme Court justices weigh in on TikTok bid to avoid ban

Japanese foreign minister to attend Trump swearing-in - Nikkei

As China hacking threat builds, Biden to order tougher cybersecurity standards

Zelenskiy: Sanctions on Russian oil significantly affect Moscow's war financing

Privacy Policy
Terms Of Service

Midwest Communications, Inc.

Copyright © 2025. All Rights Reserved.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.